Why aren t more people using vascepa generics?

Why generics of Vascepa remain underused

Generic versions of Vascepa launched in 2021 after Amarin’s patents were struck down in court. Despite the lower price, uptake has stayed modest. The main reason is that many insurers still treat the drug as a specialty product and require prior authorization or step therapy before covering the generic. These restrictions slow prescriptions and frustrate both patients and physicians.

How long do the remaining patents last?
Amarin has appealed further claims, but the core patent covering the purified EPA ingredient expired in 2020. A secondary formulation patent is set to run until 2030, yet courts have already ruled it invalid for the 1-gram capsule strength. Generic makers are therefore free to sell at current prices while litigation drags on.

What are the price differences patients actually see?
Cash prices for branded Vascepa average around $300–$350 for a month’s supply. Generic icosapent ethyl lists between $50 and $120 depending on the pharmacy and coupon programs. Even so, high-deductible plans and coinsurance can erase most of the savings until the deductible is met.

Why do some doctors still write for the brand?
A portion of cardiologists continue to prescribe the reference product because they are familiar with its REDUCE-IT trial data and have not yet updated electronic health record favorites or prior-authorization templates. Switching requires an extra step that busy practices often skip.

Can patients get the generic without insurance hurdles?
Yes. Cash-pay programs at Costco, Mark Cuban Cost Plus, and GoodRx routinely offer icosapent ethyl below $50 for 120 capsules. Patients willing to bypass insurance and use these channels report the fastest access, though they must track quantities themselves.

How does Vascepa compare with OTC fish-oil supplements?
Prescription icosapent ethyl is highly purified and contains no DHA, the component linked to LDL increases in some studies. Over-the-counter products mix EPA and DHA and are not proven to lower cardiovascular risk in the same patient population. Guidelines therefore still list prescription-grade icosapent ethyl as the preferred option for patients with established heart disease and high triglycerides.

What happens to coverage once more generics enter?
Additional manufacturers have already filed ANDAs. As competition widens, pharmacy benefit managers are expected to drop prior-authorization requirements and move the drug to lower tiers. Early signals from 2024 plan year formularies show two regional insurers removing step edits for generic icosapent ethyl, suggesting broader access may follow.